http://www.businesswire.com/portal/site ... ewsLang=en
Opexa Therapeutics to Present at the Cambria Capital Investor Meeting
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis and diabetes, is scheduled to present at the Cambria Capital Investor Meeting in Salt Lake City on Thursday, April 9, 2009 at 3:45 p.m. MST.
Neil K. Warma, President and CEO, is scheduled to present. The purpose of the presentation will be to update investors on the current business developments and goals for 2009.
No webcast or archive will be available for this presentation. Those investors wishing to attend should contact Cambria Capital at (877) 224-0477 toll free, (801) 320-9606 main or by email at email@example.com
, no later than Wednesday, April 8, 2008.
About Cambria Capital, LLC
Cambria Capital, LLC (“Cambria”) is an investment banking and securities brokerage firm with offices in Salt Lake City, Los Angeles and San Francisco. Cambria’s mission is to facilitate the growth and development of promising companies at all stages of development by providing capital and a wide variety of financial advisory services. The financing arranged by Cambria originates from a number of sources, including the firm’s principals and Cambria’s network of high net-worth individuals and institutional investors. Cambria employs a number of corporate finance structures, including PIPEs (Private Investments in Public Equities), private placements of equity and debt securities and reverse mergers. Cambria is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Cambria website at www.cambriacapital.com